Home » VOYAGER PHARMACEUTICAL REPORTS PROGRESS IN ENROLLMENT FOR ALZHEIMER'S STUDY
VOYAGER PHARMACEUTICAL REPORTS PROGRESS IN ENROLLMENT FOR ALZHEIMER'S STUDY
Voyager Pharmaceutical has announced its progress in enrolling subjects into the ALADDIN studies, Phase III double-blind, placebo-controlled trials investigating the safety and efficacy of VP4896 in the treatment of mild-to-moderate Alzheimer's disease.
A total of 64 sites are now enrolling subjects for the study. Fifty-three of the sites are located in the U.S. and Canada, with the remaining 11 in Australia. During the first two-and-a-half months of recruitment, these sites have enrolled 57 subjects.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May